TC
KNSA icon

Truvestments Capital’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Truvestments Capital’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.2K Sell
284
-226
-44% -$11.7K ﹤0.01% 700
2026
Q1 		$24.6K Sell
510
-117
-19% -$5.18K ﹤0.01% 604
2025
Q4 		$25.9K Hold
627
– – ﹤0.01% 543
2025
Q3 		$24.3K Sell
627
-202
-24% -$6.56K ﹤0.01% 557
2025
Q2 		$22.9K Hold
829
– – ﹤0.01% 508
2025
Q1 		$18.4K Hold
829
– – ﹤0.01% 570
2024
Q4 		$16.4K Buy
829
+290
+54% +$6.62K ﹤0.01% 522
2024
Q3 		$13.5K Buy
+539
New +$13.1K ﹤0.01% 542
2024
Q2 		– Sell
-447
Closed -$8.82K – 470
2024
Q1 		$8.82K Hold
447
– – ﹤0.01% 505
2023
Q4 		$7.84K Hold
447
– – ﹤0.01% 537
2023
Q3 		$7.76K Hold
447
– – ﹤0.01% 469
2023
Q2 		$6.29K Hold
447
– – ﹤0.01% 505
2023
Q1 		$4.81K Buy
+447
New +$5.89K ﹤0.01% 517

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Truvestments Capital's KNSA Position: Q2 2026 in Review

Truvestments Capital reduced its Kiniksa Pharmaceuticals (KNSA) stake by 44% in Q2 2026, selling an estimated $11.7K and leaving 284 shares worth $18.2K. The position accounts for ﹤0.01% of the portfolio, ranked #700.

Truvestments Capital first reported a position in KNSA in Q1 2023 and has held it in 13 quarters since. The position peaked at $25.9K in Q4 2025. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

  • Truvestments Capital held 284 shares of Kiniksa Pharmaceuticals worth $18.2K as of Q2 2026.
  • Truvestments Capital sold 226 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $11.7K.
  • Kiniksa Pharmaceuticals made up ﹤0.01% of Truvestments Capital's portfolio in Q2 2026, its #700 holding.
  • Truvestments Capital first reported a position in Kiniksa Pharmaceuticals in Q1 2023 and has held it in 13 quarters since.
  • Truvestments Capital's Kiniksa Pharmaceuticals position peaked at $25.9K in Q4 2025.
  • 266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Truvestments Capital's 13F filing for Q2 2026, filed 12 Aug 2026.